Home・Listă Acțiuni・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Deschisă

SectorSănătate

43.1 -0.19

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

42.5

Maxim

43.62

Indicatori cheie
By Trading Economics
Venit	-56M -58M
Vânzări	11M 219M
EPS	0.39
Marjă de profit	-26.646
Angajați	778
EBITDA	-50M -30M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+50.27% upside

Dividende
By Acuity
Următoarele câștiguri	3 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-236M 2.5B
Deschiderea anterioară	43.29
Închiderea anterioară	43.1

Sentimentul știrilor

By Acuity

78%

22%

300 / 339 Clasament în Healthcare

Supernus Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 sept. 2026, 20:07 UTC

Supernus Pharmaceuticals Inc shares fell as the broader market declines under pressure from rising U.S. Treasury yields and persistent inflation concerns.

22 sept. 2026, 20:13 UTC

Supernus Pharmaceuticals Inc is declining in after-market trading, maintaining lower since Tuesday's close, with price around the middle of its one-month range.

18 sept. 2026, 20:06 UTC

Supernus Pharmaceuticals Inc shares fell sharply, reaching a low of over 3% and closing well below the 20-day moving average on Friday.

17 sept. 2026, 20:02 UTC

Supernus Pharmaceuticals Inc is trading sharply higher, rebounding from an early low to peak just before 10:30 AM, despite being below its 20-day moving average.

16 sept. 2026, 22:36 UTC

Supernus Pharmaceuticals Inc is declining in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

15 sept. 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower, extending an eight-session decline. Broader market sentiment is affected by a significant drop in the NY Empire State Manufacturing Index.

14 sept. 2026, 19:36 UTC

Supernus Pharmaceuticals Inc. is trading higher today, despite broader market pressure from rising crude oil prices and geopolitical supply concerns.

11 sept. 2026, 20:13 UTC

Supernus Pharmaceuticals Inc. shares rose in after-market trading, reflecting broader market trends amid recent inflation data and speculation of a Federal Reserve interest rate hike.

10 sept. 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower, continuing a five-session decline amid broader market trends following the European Central Bank's interest rate hike.

8 sept. 2026, 20:02 UTC

Supernus Pharmaceuticals Inc. shares are lower as the Pharmaceuticals sub-sector faces significant declines, continuing a trend from the past three sessions.

2 sept. 2026, 19:36 UTC

Supernus Pharmaceuticals is trading higher Wednesday, despite earlier pulling back from an intraday peak amid broader geopolitical tensions affecting oil prices.

1 sept. 2026, 20:09 UTC

Supernus Pharmaceuticals Inc shares are lower today amid increased market volatility and investor concerns over rising oil prices and potential Federal Reserve interest rate hikes.

31 aug. 2026, 21:02 UTC

Supernus Pharmaceuticals Inc shares are higher in after-market trading, reflecting a notable rise since Monday's close. No specific news was identified to explain the movement.

28 aug. 2026, 19:26 UTC

Supernus Pharmaceuticals Inc. shares are trading lower, continuing a trend of declines amid broader market concerns about inflation and Federal Reserve remarks on price stability.

27 aug. 2026, 20:07 UTC

Supernus Pharmaceuticals Inc shares are declining, continuing a downward trend since Wednesday. Broader market conditions may be contributing to this weakness.

26 aug. 2026, 20:08 UTC

Supernus Pharmaceuticals Inc shares are lower today, driven by declines in the Pharmaceuticals sub-sector. The stock is trading near its one-month low.

25 aug. 2026, 19:16 UTC

Supernus Pharmaceuticals Inc. shares are higher today amid a broader market rally, supported by falling crude oil prices and lower treasury yields.

24 aug. 2026, 19:26 UTC

Supernus Pharmaceuticals Inc. shares are lower, continuing a four-session decline amid broader market volatility and geopolitical tensions affecting oil supply.

21 aug. 2026, 20:01 UTC

Supernus Pharmaceuticals Inc. shares are lower today, aligning with broader market weakness and finishing at the lowest point observed during the session.

20 aug. 2026, 21:01 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of three consecutive daily declines amid broader market pressures.

18 aug. 2026, 19:36 UTC

Supernus Pharmaceuticals Inc is trading higher, maintaining upward momentum since Monday. The stock remains above its 20-day moving average and near a one-month high.

17 aug. 2026, 19:26 UTC

News

Supernus Pharmaceuticals Inc is featured in a cautionary analysis from Yahoo Finance, citing below-average sales growth and declining cash flow margin. The stock is roughly flat today.

14 aug. 2026, 19:16 UTC

Macro Event

Supernus Pharmaceuticals Inc shares are higher, maintaining momentum since Thursday amid broader market caution following a decline in U.S. retail sales.

13 aug. 2026, 19:16 UTC

Supernus Pharmaceuticals Inc shares are lower Thursday, pulling back from an early high. No specific news was identified to explain the movement.

12 aug. 2026, 19:51 UTC

Supernus Pharmaceuticals shares are higher amid positive market sentiment following an inflation report and strength in technology stocks.

11 aug. 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower as the Pharmaceuticals sector declines. The stock is trading with unusually high volume today.

10 aug. 2026, 22:46 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Monday's close amid broader market reassessments of interest rate hikes.

7 aug. 2026, 19:31 UTC

Supernus Pharmaceuticals Inc. is trading higher, influenced by an advancing overall market amid positive macroeconomic indicators, despite ongoing geopolitical tensions.

6 aug. 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday's close, amid unusually high market volume.

5 aug. 2026, 20:03 UTC

Supernus Pharmaceuticals Inc shares are higher Wednesday, driven by high market volume and broader positive sentiment amid declining oil prices and geopolitical optimism.

Comparație

Modificare preț

Supernus Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

50.27% sus

Prognoză pe 12 luni

Medie 65.2 USD 50.27%

Maxim 67 USD

Minim 63 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSupernus Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Supernus Pharmaceuticals Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

300 / 339 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.